We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

108 hedge funds and large institutions have $298M invested in ChemoCentryx, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 45 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

2% more funds holding

Funds holding: 106108 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9% less call options, than puts

Call options by funds: $1.48M | Put options by funds: $1.63M

13% less capital invested

Capital invested by funds: $344M → $298M (-$45.2M)

33% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 45

Holders
108
Holders Change
+2
Holders Change %
+1.89%
% of All Funds
2.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
30
Reduced
45
Closed
10
Calls
$1.48M
Puts
$1.63M
Net Calls
-$152K
Net Calls Change
-$50K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$73M -$909K -86,237 -1%
BlackRock
2
BlackRock
New York
$29.8M -$770K -73,020 -3%
WA
3
Wasatch Advisors
Utah
$25.3M -$695K -65,931 -3%
FCM
4
Farallon Capital Management
California
$15.8M +$3.16M +300,000 +26%
Franklin Resources
5
Franklin Resources
California
$15.1M -$665K -63,100 -4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$14.8M +$327K +30,990 +2%
CG
7
Carmignac Gestion
France
$13.4M -$812K -76,981 -6%
Renaissance Technologies
8
Renaissance Technologies
New York
$9.64M +$1.17M +111,100 +14%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$8.93M -$821K -77,891 -9%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$7.03M +$6.79M +644,305 New
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$6.9M +$889K +84,290 +15%
NCM
12
Nantahala Capital Management
Connecticut
$6.8M -$211K -20,000 -3%
State Street
13
State Street
Massachusetts
$5.32M -$80.4K -7,629 -2%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.64M +$874K +82,918 +33%
PAM
15
Panagora Asset Management
Massachusetts
$3.54M +$1.15K +109 +0%
TCIM
16
TIAA CREF Investment Management
New York
$3.4M -$209K -19,845 -6%
Northern Trust
17
Northern Trust
Illinois
$3.27M -$5.13K -487 -0.2%
Ameriprise
18
Ameriprise
Minnesota
$2.89M +$1.37M +130,109 +97%
Arrowstreet Capital
19
Arrowstreet Capital
Massachusetts
$2.4M +$97.5K +9,242 +4%
Goldman Sachs
20
Goldman Sachs
New York
$2.35M -$27K -2,561 -1%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$2.35M -$136K -12,900 -6%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$2.34M -$474K -44,938 -17%
BBA
23
Baker Bros. Advisors
New York
$2.26M -$2.18M -207,000 -50%
SCM
24
Sio Capital Management
New York
$1.85M +$1.78M +169,257 New
OAM
25
Oxford Asset Management
United Kingdom
$1.73M +$274K +26,006 +20%

CCXI Hedge Fund Activity: Q4 2018 in Review

108 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q4 2018, worth a combined $298M — down 13% from $344M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CCXI positions and 10 closed out — a net gain of 2 holders — while 30 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $6.79M. The largest seller was Baker Bros. Advisors, cutting an estimated $2.18M.

  • 108 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q4 2018, up from 106 in Q3 2018.
  • Funds reported $298M of ChemoCentryx, Inc. stock for Q4 2018, down 13% quarter-over-quarter.
  • 12 funds opened new ChemoCentryx, Inc. positions in Q4 2018 and 10 closed out, a net change of +2 holders.
  • The largest ChemoCentryx, Inc. buyer in Q4 2018 was Fidelity Investments, an estimated $6.79M added.
  • The largest ChemoCentryx, Inc. seller in Q4 2018 was Baker Bros. Advisors, an estimated $2.18M sold.

Based on aggregated 13F filings for Q4 2018.